Pre-existing cardiovascular disease increases risk of atrial arrhythmia and mortality in cancer patients treated with Ibrutinib

Pre-existing cardiovascular disease increases risk of atrial arrhythmia and mortality in cancer patients treated with Ibrutinib

Abstract Background Ibrutinib is a Bruton’s tyrosine kinase inhibitor used in the treatment of hematological malignancies. The most common cardiotoxicity associated with ibrutinib is atrial arrhythmia (atrial fibrillation and flutter). It is known that patients with cardiovascular disease (CVD) are...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Juan Carlo Avalon, Jacob Fuqua, Tyler Miller, Seth Deskins, Chelby Wakefield, Austin King, Sonya Inderbitzin-Brooks, Christopher Bianco, Lauren Veltri, Wei Fang, Michael Craig, Abraham Kanate, Kelly Ross, Midhun Malla, Brijesh Patel
Formato: article
Lenguaje:EN
Publicado: BMC 2021
Materias:
Ibrutinib
Atrial fibrillation
Cardio-oncology
Cardiovascular disease
Arrhythmia
Hematologic malignancy
Diseases of the circulatory (Cardiovascular) system
RC666-701
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Acceso en línea:https://doaj.org/article/dd55526f958e4bdbbb25c6d0cb0df70b
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/dd55526f958e4bdbbb25c6d0cb0df70b

Ejemplares similares